UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Ublituximab (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ULTIMATE I
- Sponsors TG Therapeutics Inc
- 02 Feb 2018 According to a TG Therapeutics media release, trial is currently enrolling and complete enrollment is expected in the first quarter of 2019.
- 15 Sep 2017 According to a TG Therapeutics media release, global ULTIMATE I and II trials are being led by Dr. Lawrence Steinman.
- 07 Sep 2017 Status changed from planning to recruiting.